%0 Journal Article
%T Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
%A Metro, Giulio
%A Di Maio, Massimo
%J Translational Lung Cancer Research
%D 2018
%B 2018
%9 
%! Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
%K 
%X We agree with dr. Addeo and dr. Banna when they emphasize that the biology of non-small cell lung cancer (NSCLC) is complex, and that a single biomarker is probably not exhaustive in order to optimally predict (either positively or negatively) the potential efficacy of immune checkpoint inhibitors.
%U https://tlcr.amegroups.org/article/view/23045
%P S294-S296
%@ 2226-4477